natgillin/translations-raw huggingface dataset:
In another exemplary embodiment, the disease is a member selected from arthritis, rheumatoid arthritis, an inflammatory bowel disease, psoriasis, multiple sclerosis, a neurodegenerative disorder, congestive heart failure, stroke, aortic valve stenosis, kidney failure, lupus, pancreatitis, allergy, fibrosis, anemia, atherosclerosis, a metabolic disease, a bone disease, a cardiovascular disease, a chemotherapy/radiation related complication, diabetes type I, diabetes type II, a liver disease, a gastrointestinal disorder, an ophthamological disease, allergic conjunctivitis, diabetic retinopathy, Sjogren's syndrome, uvetitis, a pulmonary disorder, a renal disease, dermatitis, HIV-related cachexia, cerebral malaria, ankylosing spondolytis, leprosy, anemia and fibromyalgia. In another exemplary embodiment, the disease is actinic keratosis. 
Spoj za uporabu u liječenju ili sprječavanju bolesti izabrane između psorijaze, atopijskog dermatitisa, psorijaznog artritisa, reumatoidnog artritisa, upalne bolesti crijeva, multiple skleroze, neurodegerativnog poremećaja, kongestivne srčane insuficijencije, moždanog udara, stenoze zaliska aorte, zatajenja bubrega, pankreatitisa, alergije, anemije, ateroskleroze, bolesti metabolizma, kardiovaskularne bolesti, komplikacije povezane s kemoterapijom/zračenjem, dijabetesa tipa I, dijabetesa tipa II, bolesti jetre, gastrointestinalnog poremećaja, oftalmološke bolesti, alergijskog konjuktivitisa, dijabetičke retinopatije, Sjogren-ovog sindroma, uveitisa, plućnog poremećaja, bolesti bubrega, kaheksije povezana s HIV-om, cerebralne malarije, ankilozantnog spondilitisa, lupusa, dermatitisa, lepre, fibromijalgije, kontaktnog dermatitisa, ekcema, bolest suhih očiju i Behcet-ove bolesti kod ljudi ili životinja, naznačeno time da spoj ima strukturu koja je izabrana između:
Examples of suitable anti-anxiety agents for use in combination with the compounds of the present invention include benzodiazepines (e.g., diazepam, lorazepam, oxazepam, alprazolam, chlordiazepoxide, clonazepam, chlorazepate, halazepam and prazepam), 5HT1A receptor agonists (e.g., buspirone, flesinoxan, gepirone and ipsapirone), and corticotropin releasing factor (CRF) antagonists. 
Primjeri prikladnih sredstava protiv anksioznosti za primjenu u kombinaciji sa spojevima prikazanog izuma uključuju benzodiazepine (npr., diazepam, lorazepam, oksazepam, alprazolam, klordiazepoksid, klonazepam, klorazepat, halazepam i prazepam), agonisti SHT1A receptora (npr., buspiron, flesinoksan, gepiron i ipsapiron) i antagonisti faktora za oslobađanje kortikotropina (CRF).
Number of mice PBS 
Broj međunarodne prijave:
In the method of producing a piceatannol-containing composition according to the present invention, the passion fruit seed is preferably a raw passion fruit seed or a dried passion fruit seed, which is obtained by drying the raw passion fruit seed. 
Postupak proizvodnje sastava koji sadrži piceatanol, prema bilo kojem od zahtjeva 7 do 9, naznačen time, da sjeme Passiflora edulis sims je sirovo sjeme Passiflora edulis sims, ili je to osušeno sjeme Passiflora edulis sims, koje je dobiveno sušenjem sirovog sjemena Passiflora edulis sims.
The arrester according to claim 1, characterized in that the mutually displaced intermediate electrodes are arranged along a line coinciding with the longitudinal axis of the insulating body. 
Gromobran u skladu s patentnim zahtjevom 1, naznačen time što se međusobno razmaknute međuelektrode (4) nalaze na liniji koja se poklapa s uzdužnom osi izolirajućeg tijela (1).
Use of 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of Huntington's disease (HD). 
Uporaba 1-(2-izopropoksietil)-2-tiokso-1,2,3,5-tetrahidro-pirolo[3,2-d]pirimidin-4-ona ili njegove farmaceutski prihvatljive soli naznačena time da je za proizvodnju lijeka za liječenje Huntingtonove bolesti (HD).
When emptied the bottle is collapsed and will take up little space during transportation for recycling. 
Kad se isprazni, bocu se stlači i ona će tijekom transporta do recikliranja zauzimati mali prostor.
Also provided is a method for the use of such pharmaceutical formulations for the treatment of heart failure, including but not limited to: acute (or decompensated) congestive heart failure, and chronic congestive heart failure; particularly diseases associated with systolic heart dysfunction. Also provided is a synthesis of omecamtiv mecarbil comprising admixing methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-caboxylate and phenyl (6-methylpyridin-3-yl)carbamate in the presence of a trialkylamine base to form omecamtiv mecarbil. 
Postupak za pripravu dihidroklorid hidratne soli omekamtiv mekarbila naznačen time što sadrži miješanje metil 4-(3-amino-2-fluorobenzil)piperazin-1-karboksilata i fenil (6-metilpiridin-3-il)karbamata u prisutnosti trialkilamin baze kako bi nastao omekamtiv mekarbil; i nadalje sadrži kristaliziranje omekamtiv mekarbila u prisutnosti vodene klorovodične kiseline i alkoholnog otapala kako bi nastala dihidroklorid hidratna sol omekamtiv mekarbila, na primjer, pri čemu alkoholno otapalo sadrži izopropilni alkohol.
The device according to claim 1, wherein the perforated sheet comprises a plurality of circular shaped holes. 
Uređaj sukladno zahtjevu 1, gdje perforirani list sadrži veći broj kružno oblikovanih rupa.
a linear or branched alkyl group containing from 1 to 10 carbon atoms and optionally substituted with one or more hetereoatoms such as halogen (selected from F, Cl, Br or I), oxygen, and nitrogen, the latter optionally in the form of a pendant basic nitrogen functionality, or 
- linearna alkilna grupa ili razgranata alkilna grupa koja sadrži od 1 do 10 atoma ugljika i fakultativno je zamijenjena jednim ili više heteroatoma poput atoma halogena (odabran između F, Cl, Br ili 1), atoma kisika ili atoma dušika, koji je fakultativno u obliku odgovarajuće osnovne azidne funkcije, ili
A polymer composition comprising a co-processed microfibrillated cellulose and inorganic particulate material composition, wherein the microfibrillated cellulose has a fibre steepness of from 20 to 50, optionally wherein the co-processed microfibrillated cellulose and inorganic particulate material composition is substantially homogeneously dispersed in the polymer composition. 
HR P20171343 T1 Mješavina polimera koja sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala, naznačena time što mikrofibrilirana celuloza ima močivost vlakana od 20 do 50, gdje suobrađena mješavina mikrofibrilirane celuloze i anorganskog partikuliranog materijala može biti uglavnom homogeno dispergirana u mješavini polimera.
E is pyrrolidine or piperidine optionally substituted 
E je pirolidin ili piperidin, izborno supstituiran s hidroksilnom skupinom; i
Polyethylene glycol for use according to any one of claims 1 to 6, wherein the topical administration is to one or more sites exhibiting an active viral infection or to a site where there are no signs of an active infection but where active infection is known to occur or is expected to occur. 
Polietilen glikol za uporabu prema bilo kojem zahijevu od 1 do 6, naznačen time, da se topikalna primjena vrši na jednom ili više mjesta koja su izložena aktivnoj virusnoj infekciji ili mjesta gdje više nema znakova aktivne infekcije, ali gdje se aktivna infekcija obično pojavljuje ili se očekuje njezina pojava.
a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the anti-human TSLP receptor antibody according to claim 1(1), wherein the host cell expresses said antibody. 
(d) stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži bazni slijed koji kodira varijabilno područje lakog lanca protutijela protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 1(1), gdje stanica domaćin eksprimira navedeno protutijelo.
If necessary, inserts 25 placed in recesses that might still visible after constructing the floors 15-17. 
Ako je potrebno, u udubljenja koja bi mogla biti vidljiva i nakon oblikovanja podova 15-17, postavljaju se umetci 25.
an adhesive layer, applied over and to the optional underlying liner (i) when present; 
sloj ljepila, kojeg se primjenjuje preko i na izbornu osnovnu oblogu (i), kada je prisutan;
The PET container of claim 3 wherein the wall, when subjected to temperature modulated differential scanning calorimetry and analyzed in the temperature range of from 0° C. to 325° C. at a heating rate of 5°/min, exhibits a first endothermic glass transition temperature and a second endothermic transition temperature higher than the first transition temperature. 
PET posuda iz patentnog zahtjeva 1 gdje zid, kada je podvrgnut temperaturom moduliranoj diferencijalnoj skenirajućoj kalorimetriji i analiziran u opsegu temperature od 0% C. do 325" C. pri brzini zagrijavanja od 5 *C/min, izlaže temperaturu prvog endotermnog prelaza stakla i temperaturu drugog endotermnog prelaza stakla višu od prve temperature prelaza.
wherein a transmission delivery system descriptor including the identifier of the PLP, the identifier of the transmission system, and a guard interval fields in a TS loop of the NIT maps transport streams to PLPs in data slices of the transmission systems. The method according to claim 1, wherein a value of the guard interval is one of 1/128 and 1/64. The method according to claim 1 or claim 2, wherein the NIT includes an identifier of a transport stream and an identifier of a network. 
Postupak prema zahtjevu 1, gdje je vrijednost aktivnog OFDM polja trajanja simbola jedna od 448 µs na 4k brzih Fourierovih transformacija (FFT), mod za prijenosni sustav od 8 MHz širine pojasa i 448 x (8/6) µs na 4k FFT mod za prijenosni sustav od 6 MHz širine pojasa. Uređaj prema zahtjevu 1 ili 2, gdje NIT obuhvaća identifikator prijenosnog toka i identifikator mreže.
condensing a compound represented by the formula (IX): 
(5) kondenziranje spoja prikazanog formulom (IX):
Determine % solids as described under Solids content. 
% krutina se određuje kako je opisano pod Sadržaj čvrste tvari.
The floor underlayment of claim 10, further comprising a heating element positioned in at least one of the receiving cavities. 
Podni sklop u skladu s patentnim zahtjevom 6, naznačen time što je navedeni grijaći element (5) jedno od žice i cjevovoda za tekućinu.
The solid oral extended release pharmaceutical dosage form of anyone of claims 1, 3, 5 and 7, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da oblik doziranja kada je ispitivan u komparativnoj kliničkoj studiji je bioekvivalentan sa komercijalnim proizvodom OxyContin™.
This invention relates to the unexpected discovery that the claimed rapamycin carbohydrate derivatives have improved pharmacological properties as compared to underivatized rapamycin. 
Ovaj se izum odnosi na neočekivano otkriće da ovdje objavljeni ugljikohidratni derivati rapamicina imaju poboljšana farmakološka svojstva u usporedbi s nederiviranim rapamicinom.
The process of claim any of the previous claims, wherein the remineralized water has a turbidity value of lower than 5.0 NTU, lower than 1.0 NTU, lower than 0.5 NTU, or lower than 0.3 NTU. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu remineralizirana voda ima vrijednost zamućenosti od ispod 5.0 NTU, manje od 1.0 NTU, manje od 0.5 NTU, ili manje od 0.3 NTU.
when in a compound of formula I R1 represents R1'-CH2-CH2-, treating a compound of formula IX with a reducing agent wherein R1' represents C1-6 alkyl or C3-8 cycloalkyl-C0-4 alkyl or aryl-C0-4 alkyl, wherein any alkyl group may be optionally substituted by one or more halogen groups and the C3-8 cycloalkyl group may be optionally substituted by one or more substituents independently selected from C1-4 alkyl, halogen and aryl, or R1' represents a group of formula (i) wherein n represents 2 and R4 and R5 represent H, or a group of formula (ii) wherein p represents 2 and R4 and R5 represent H; and R2 and R3 have the meaning described in claim 1; or 
kada u spoju formule I, R1 predstavlja R1,-CH2-CH2-, tretiranja spoja formule IX s redukcijskim sredstvom [image] pri čemu Rr predstavlja C1-6 alkil ili C3-a cikloalkil-C0-4 alkil ili aril-C0-4 alkil, gdje bilo koja alkilna skupina po izboru može biti supstituirana s jednim ili više skupina halogena i C3-a cikloalkilna skupina po izboru može biti supstituirana s jednim ili više supstituenata neovisno odabranih od C1-4 alkila, halogena i arila, ili R1' predstavlja skupinu formule (i) gdje n predstavlja 2, a R4 i R5 predstavljaju H ili skupinu formule (ii) gdje p predstavlja 2, a R4 i R5 predstavljaju H; i R2 i R3 imaju značenje opisano u patentnom zahtjevu 1; ili
Method according to any one of claims 1 to 3, characterised in that the AB-aggregates have a size of 50 nm to 15 µm, preferably from 100 nm to 10 µm, especially from 200 nm to 5 µm. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da Aß-agregati imaju veličinu od 50 nm do 15 µm, poželjno od 100 nm do 10 µm, posebno pogodno od 200 nm do 5 µm.
and R2 are independently hydrogen, optionally substituted C1-6 alkyl, or a group -D-E, in which D is a covalent bond or alkylene, and E is optionally substituted phenyl, optionally substituted cycloalkyl, optionally substituted alkenyl, or optionally substituted alkynyl, and 
i R2 su nezavisno vodik, opcijski supstituirani C1-6 alkil, ili grupa -D-E, u kojoj je D kovalentna veza ili alkilen, i E je opcijski supstituirani fenil, opcijski supstituirani cikloalkil, opcijski supstituirani alkenil, ili opcijski supstituirani alkinil, i
expressing an antibody attached to an amino acid motif that can be recognized by an isoprenoid transferase; 
(a) ekspresiju protutijela vezanog na aminokiselinski motiv koji se može prepoznati izoprenoid transferazom;
In another aspect, embodiments of the present invention encompass the use of a sponge as described herein for the treatment of an injury such as a wound, a hemorrhage, damaged tissue and/or bleeding tissue. 
Spužva prema bilo kojem od zahtjeva 1 do 5 naznačena time da je za uporabu za liječenje ozljede odabrane iz skupine koju čine rana, krvarenje, ozlijeđeno tkivo i/ili krvarenje tkiva.
In some embodiments, the third translation initiation region comprises a DsbA signal sequence. In some embodiments, the third translation initiation region comprises a PhoA signal sequence. In another aspect, the invention provides polynucleotide comprising (1) a first translation initiation region (TIR) operably linked to a polynucleotide encoding an antibody heavy chain, wherein the TIR comprises a co-translation prokaryotic secretion signal sequence; and (2) a second TIR operably linked to a polynucleotide encoding an antibody light chain, wherein the second TIR comprises a co-translation or post-translation prokaryotic secretion signal sequence, whereby upon expression of the antibody in a host cell, the heavy and light chains are folded and assembled to form a biologically active antibody. 
Postupak priprave protutijela, naznačen time, da spomenuti postupak obuhvaća kultiviranje stanice domaćina koja sadrži polinukleotid s (1) prvim područjem inicijacije translacije (TIR) koje je funkcionalno povezano s polinukleotidom koji kodira protutijelo jakog lanca, pri čemu TIR obuhvaća signalnu sekvencu DsbA prokariotske kotranslacijske sekrecije, odabranu iz skupine koja se sastoji od SEQ ID NO:36 do SEQ ID NO:39, SEQ ID NO:41 i SEQ ID NO:42; te s (2) drugim TIR-područjem koje je funkcionalno povezano s polinukleotidom koji kodira protutijelo slabog lanca, dok drugo TIR-područje obuhvaća signalnu sekvencu prokariotske kotranslacijske ili posttranslacijske sekrecije, pri čemu se nakon ekspresije protutijela u stanici domaćina, jaki i slabi lanci preklapaju i sklapaju u svrhu tvorbe biološki djelotvornog protutijela.
A sealed container comprising a sealable container according to any of claims 1 to 10 and a lidding film sealed thereto. 
Posuda prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu je tanki film pričvršćen.
at least one conventional biocide selected from the group consisting of zinc pyrithione, copper pyrithione, zinc ethylene bis dithiocarbamate, tolylfluanide, dichlofluanide, 4,5-dichloro-2-N-octyl-4-isothiazoline-3-one, N′-tert-butyl-N-cycloprop-6-(methylthio)-1,3,5-triazine-2,4-diamine, and any combination thereof. An anti-fouling paint comprising: 
Protuobraštajni premaz prema zahtjevu 1 ili 2, naznačeno time da su konvencionalni biocidi izabrani među grupom koja se sastoji od cinkovog piritiona, bakrovog piritiona, cinkovog etilena bis ditiokarbamata, tolilfluanida, diklo-fluanida, 4,5-diklor-2-oktil-2H-izotiazol-3-ona, N'-tert-butil-N-ciklopropil-6-(metiltio)-1,3,5,-triazin-2,4-diamina, te svake kombinacije istih.
Absorbance of the solubilised cells was read at 540nm using a Molecular Devices ThermoMax microplate reader. 
Absorbancija suspenzije stanica očita se pri 450 nm na čitaču mikrotitarskih pločica Molecular Devices ThermoMax.
The bag according to claim 1, wherein the pharmaceutical product is selected from the group consisting of: azacytidine, belinostat, bendamustine, brentuximab vedotin, bleomycin, bortezomib, busulfan, carboplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, deferoxamine, doxorubicin, epirubicin hydrochloride, fludarabine, fotemustine, fulvestrant, gemcitabine, idarubicin, ifosfamide, irinotecan hydrochloride, ixabepilone, melphalan, methotrexate, oxaliplatin, paclitaxel, pemeterxed, pentostatin, raltitrexed, romidepsin, temozolomide, thiotepa, topotecan, trabectedin, trastuzumab, and vinblastine. 
Farmaceutska vrećica u skladu s patentnim zahtjevom 8, naznačena time, da je citotoksični lijek odabran iz skupine koju tvore: azacitidin, belinostat, bendamustin, brentuksimab vedotin, bleomicin, bortezomib, busulfan, karboplatin, ciklofosfamid, citarabin, dakarbazin, daktinomicin, daunorubicin, decitabin, deferoksamin, doksorubicin, epirubicin hidroklorid, fludarabin, fotemustin, fulvestrant, gemcitabin, idarubicin, ifosfamid, irinotekan hidroklorid, iksabepilon, melfalan, metotreksat, oksaliplatin, paklitaksel, pemetreksed, pentostatin, raltitreksed, romidepsin, temozolomid, tiotepa, topotekan, trabektedin, trastuzumab i vinblastin.
The pharmaceutical composition of claim 2, wherein the at least one acidifying agent is selected from citric acid, acetic acid, and phosphoric acid. The pharmaceutical composition of claim 1, further comprising at least one humectant. 
Komplet prema patentnom zahtjevu 14, naznačen time, što je najmanje jedno sredstvo za zakiseljavanje odabrano iz jedne ili više limunske kiseline, octene kiseline i fosforne kiseline, i naznačen time, što je najmanje jedno sredstvo za želiranje hidroksipropilceluloza.
The pharmaceutical composition according to claim 2, comprising 80 mg of the hemisulfate salt of Compound (I). 
Farmaceutska kompozicija u skladu sa patentnim zahtjevom 2, koja sadrži 80 mg hemisulfat soli spoja (1).
is selected from hydrogen, CORa, COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkenynyl; 
Ra se bira između vodika, COR,, COOR, supstituiranog ili nesupstituiranog C;-C,> alkila, supstituiranog ili nesupstituiranog C2-Cpx_ alkenila, supstituiranog ili nesupstituiranog C2-Ci2_ alkinila, 1 supstituiranog ili nesupstituiranog C4-C;2 alkeninila;
According to a preferred embodiment, the composition comprises at least two groups of coated particles differing in the amount and/or the composition of release modifying material and/or comprising different active agents. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 2 do 5, naznačen time,da obuhvaća najmanje dvije skupine obloženih čestica, koje se razlikuju u količini i/ili sastavu materijala koji modificira oslobađanje.
A method according to any one of the preceding claims, wherein said cosmetic composition comprises a cosmetically acceptable vehicle and optionally further cosmetically active substances, selected from the group comprising vitamins, essential fatty acids, ceramides, proteins or protein hydrolysates, amino acids, polyols, plant extracts and hydroxy acids, antioxidants, retinol and retinol palmitate, plant meristematic and stem cells. 
Postupak prema bilo kojem od prethodnih zahtjeva, gdje taj kozmetički pripravak sadrži kozmetički prikladan nosač 1 po izboru dodatne kozmetički aktivne tvari, odabrane iz skupine koju čine vitamini, esencijalne masne kiseline, ceramidi, proteini ili proteinski hidrolizati, aminokiseline, polioli, biljni ekstrakti i hidroksi kiseline, antioksidansi, retinol i retinol palmitat, biljne meristemske 1 matične stanice.
The gene construction according to claim 6, which is an adeno-associated vector serotype 9 (AAV9) comprising a CAG promoter operably linked to SEQ ID NO: 1 (co-hu-SFMD), wherein said gene construction is designated as AAV9-CAG-co-hu-SFMD. 
Genski konstrukt u skladu s patentnim zahtjevom 6, naznačen time što je adenoasocirani vektor serotip 9 (AAV9), koji sadrži promotor GAG, operativno povezan sa SEQ 10 NO: 1 (co-hu-SFMOQ), gdje je navedeni genski konstrukt označen kao AAV9-GAG-co-hu-SFMO.
The optical element according to claims 7 or 8, wherein the exit surface of the optical element has a tilted upper portion which in use is to shade a relatively lower portion of the exit surface from snow and/or dust. 
Optički element (OP) u skladu sa patentnim zahtjevom 5 ili 6, pri čemu izlazna površina optičkog elementa ima nagnuti gornji dio koji tijekom primjene štiti relativno niži dio izlazne površine od snijega i/ili prašine.
manage mobility of DMR Terminals via the Registrar, 
- upravlja mobilnošću DMR terminala putem registrara,
The two mixtures received are blended and filled up with alpha lactose monohydrate to 12000 g. 
Dvije dobivene smjese se pomiješaju i nadopune s alfa laktoza monohidratom do 12000 g.
FIG. 12 shows a cross-sectional view of the holding member 28, which is movable as shown by the arrow 36 . 
Slika 12 prikazuje pogled na poprečni presjek člana za držanje 28, koji se može pomicati, kao što je to prikazano strelicom 36.
wherein one or more hydrogen atoms of the alkyl group may be replaced by fluorine, and/or of a stereoisomeric form of the compound of the formula I and/or mixtures of these forms, and/or their pharmaceutically acceptable salts, and with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4-methyl-phenyl, 4-methoxy-phenyl, 4-acetoxyphenyl, 2-chloro-phenyl, 3,4-dichlorophenyl, and with the proviso if R5 is methyl and R2, R3 and R4 are equal to H and X is a phenyl residue, the residue A is not phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 4-methyl-phenyl, 4-ethyloxy-phenyl, 3-trifluoromethyl-phenyl, 2-thiophenyl or 4-methylthiophenyl, and with the proviso if R5 is methyl and R2 is methyl and R3 and R4 are equal to H and A is equal to 4-fluoro-phenyl, the residue X is not phenyl. 
= H, (C1-C6)-alkil-; gdje jedan ili više vodikovih atoma iz alkilne skupine mogu biti zamijenjeni s fluorom, i/ili stereoizomerni oblik spoja s formulom I, i/ili smjese navedenih oblika, i/ili njihove farmaceutski prihvatljive soli, te pod uvjetom da ako R5 je metil i R2, R3 i R4 su jednaki H i A je jednak 4-fluoro-fenil, ostatak X nije fenil, 4-fluoro-fenil, 4-kloro-fenil, 4-metil-fenil, 4-metoksi-fenil, 4-acetoksifenil, 2-kloro-fenil, 3,4-diklorofenil, te pod uvjetom da ako R5 je metil i R2, R3 i R4 su jednaki H i X je fenilni ostatak, A nije fenil, 4-fluoro-fenil, 4-kloro-fenil, 4-metil-fenil, 4-etiloksi-fenil, 3-trifluorometil-fenil, 2-tiofenil ili 4-metiltiofenil, i pod uvjetom da ako R5 je metil i R2 je metil i R3 i R4 su jednaki H i A je jednak 4-fluoro-fenil, ostatak X nije fenil.